CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 200 target
Drug / intervention
Methylphenidate +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03772834
NCT03772834Phase 3ActiveOn Track
CompareCT.gov

A Combination Therapy to Treat Cancer-Related Fatigue - NCI R01

M.D. Anderson Cancer Center·interventional·Posted Dec 11, 2018·Updated May 4, 2026

In Brief

A Phase 3 clinical trial evaluating Exercise Intervention, Methylphenidate, and 4 other interventions for Prostate Carcinoma. Active but no longer recruiting, targeting 200 participants across 1 site.

Detailed Summary

This phase II/III trial studies how well methylphenidate and exercise work in reducing cancer-related fatigue in patients with prostate cancer. Methylphenidate is a type of central nervous system stimulant that can improve cognitive ability, mainly in memory and cognitive function. Exercise can improve mood and the physical aspects of cancer-related fatigue. Giving methylphenidate in combination with exercise may work better in reducing cancer-related fatigue in patients with prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3Active
201920202021202220232024202520262027
First PostedDec 11, 2018
Enrollment StartMar 25, 2019
Primary CompletionNov 30, 2026
TodayJul 1, 2026
Enrollment to primary: 7.7 yearsPosted 7.6 years agoPrimary completion in 5 months

Interventions

Exercise Interventionbehavioral

Undergo resistance training and walking

Methylphenidatedrug

Given PO

Placeboother

Given PO

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies

Stretchingother

Undergo stretching